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Abstract
Background and objective The long-QT syndrome (LQTS)
is associated with premature sudden cardiac deaths affect-
ing whole families and is caused by mutations in genes
encoding for cardiac proteins. When the same mutation is
found in different families (recurrent mutations), this may
imply either a common ancestor (founder) or multiple de
novo mutations. We aimed to review recurrent mutations in
patients with LQTS.
Methods By use of our databases, we investigated the
number of mutations that were found recurrently (at least
three times) in LQT type 1–3 patients in the Netherlands.
We studied familial links in the apparently unrelated
probands, and we visualised the geographical distribution
of these probands. Our results were compared with
published literature of founder effects in LQTS outside
the Netherlands.
Results We counted 14 recurrent LQT mutations in the
Netherlands. There are 326 identified carriers of one of
these mutations. For three of these mutations, familial links
were found between apparently unrelated probands.
Conclusion Whereas true LQT founder mutations are
described elsewhere in the world, we cannot yet
demonstrate a real founder effect of these recurrent
mutations in the Netherlands. Further studies on the
prevalence of these mutations are indicated, and
haplotype-sharing of the mutation carriers is pertinent
to provide more evidence for founder mutation-based
LQTS pathology in our country.
Keywords Long-QT syndrome.Arrhythmia.Founder
mutation.Genetics
Introduction
The long-QT syndrome (LQTS) is an autosomal domi-
nant, inherited, primary electrical cardiac disease. It is
characterised by structurally normal hearts in which
serious ventricular tachyarrhythmias occur, also known
as torsades de pointes, which may lead to ventricular
fibrillation and sudden cardiac death. The electrocardio-
graphic signature of LQTS is prolongation of the rate-
corrected QT interval on the electrocardiogram. The
estimated prevalence is 1:2000 [1]. Patients with LQTS
present, frequently in childhood, with typical symptoms as
fainting, often triggered by specific circumstances, among
which is physical or emotional stress. Since 1995, 12
different genes with several hundreds of causal mutations
have been identified, resulting in 12 LQT subtypes
(Table 1). Gene-specific triggers for symptoms are
p e r t i n e n ts u c ha ss w i m m i n ga n dd i v i n gi nL Q T 1a n d
arousal in LQT2, while other patients develop symptoms
during rest (LQT3) [2–6]. The expression of symptoms of
the disease is variable and not all carriers are symptomatic
(known as incomplete penetrance). Indeed, most patients
N. Hofman (*): E. Nannenberg: M. Alders
Department of Clinical Genetics, Academic Medical Center,
Meibergdreef 9,
1105 AZ, Amsterdam, the Netherlands
e-mail: n.hofman@amc.uva.nl
R. Jongbloed
Department of Clinical Genomics,
Maastricht University Medical Center,
Maastricht, the Netherlands
P. G. Postema:A. A. M. Wilde
Department of Cardiology, Academic Medical Center,
Amsterdam, the Netherlands
Neth Heart J (2011) 19:10–16
DOI 10.1007/s12471-010-0046-4present with QT prolongation and repolarisation abnor-
malities on the baseline ECG, but not all carriers have
clearly prolonged QT intervals [7]. Early treatment is
required because of a high risk of severe arrhythmias
when left untreated.
Molecular testing of LQTS patients is mandatory as
there is evidence for gene-specific triggers of events and
therapeutic efficacy [5, 8, 9]. In this manuscript, as part of
a series on Dutch founder mutations and recurrent
mutations in inherited diseases, we present an overview
of the yield of the molecular genetic tests performed in
index cases (probands) with a definite or suspected LQTS
in the Netherlands. In a number of countries, including
Finland, Sweden, Saudi Arabia, and South Africa, LQTS
founder mutations have been described, i.e., single
mutations occurring within several families which origi-
nate from common ancestors (the “founder”)[ 10–16].
However, in general, LQTS is regarded as a disease where
each family has its own “private” mutation [17–19]. In the
Netherlands, only one founder mutation is currently
known, the SCN5A mutation p.Tyr1795_Glu1796insAsp
(known as 1795insD) which gives rise to an SCN5A
overlap syndrome reported earlier in this series [20, 21].
Nevertheless, some mutations within the most commonly
involved LQT genes are identified repeatedly. In this
overview, we analyse whether these mutations are possi-
bly also founder mutations, instead of mutations which
occurred multiple times on a de novo basis.
Methods
In the Netherlands, the first cardiogenetic outpatient clinics
started in the Academic Medical Centres of Amsterdam
(AMC),UtrechtandMaastrichtinearly1996,followedbythe
other Academic Centres in later years. Molecular genetic
testing for LQTS is only performed in the Molecular Genetic
Departments of Maastricht and Amsterdam (AMC). From
both centres, we collected the genetic results of all probands
with a (suspected) diagnosis of LQTS for whom DNA was
sent to the molecular genetics facilities. A proband is the first
member of a family tobe analysed for a familialmutation. We
investigated the numberof mutations which were found in the
most common LQTS types 1–3, from 1996 to November
2009. All mutations were selected on recurrence in at least
threeprobandswhowereoriginallyassumedindependent.We
collected the pedigree data of these families and tried to
connect families with an identical mutation to each other
using genealogical information, such as place of birth and
the names of parents or grandparents. Furthermore, with
help of the postal codes of the probands,we triedto establish
whether they originated from the same region, which would
further support a common antecedent. This analysis was
based on the PC2 code (the first two numbers of the postal
code) of the probands. Data were visualised with MapInfo
Professional (MapInfo, Toronto, Canada). In the present
analysis, we excluded the previously mentioned SCN5A
mutation p.Tyr1795_Glu1796insAsp.
Table 1 Subdivision and characteristics of the different LQT types
Type of
LQTS
Gene Triggers Characteristics of
baseline ECG
Extracardiac features
LQTS 1 KCNQ1 Emotional stress/exercise/
swimming/diving
Broad T wave
morphology
–
LQTS 2 KCNH2 Arousal/emotional stress/ Low-amplitude T wave
with notching
–
LQTS 3 SCN5A Rest Long isoelectric ST
segment, bradycardia
–
LQTS 4 ANK2 – Bradycardia, atrial
arrhythmia
–
LQTS 5 KCNE1 –– –
LQTS 6 KCNE2 Arousal ––
LQTS 7 KCNJ2 Exercise U wave, extra systoles Periodic paralysis, short stature, low set ears, hypoplastic
mandible, hypotelorism, clinodactyly
LQTS 8 CACNA1C – Extremely prolonged QT
interval
Syndactyly, small teeth, autism, mental retardation, facial
dysmorphic features
LQTS 9 CAV3 –– –
LQTS 10 SCN4B –– –
LQTS 11 AKAP9 –– –
LQTS 12 SNTN1 –– –
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Since 1996, the genetic laboratories in Amsterdam (n=630)
and Maastricht (n=242) have received 872 Dutch samples
of unrelated probands for LQTS diagnostics. All cases are
included, patients with a definite diagnosis and those in
which LQTS were suspected. We combined the data of both
centres. All together, a potential disease-causing mutation
was found in 266 cases (31%). Most were “unique” familial
mutations. However, in KCNQ1 (LQT1), eight mutations
were detected in at least three families (different probands).
In KCNH2 and SCN5A (LQT2 and LQT3, respectively),
five and one recurrent mutations were found in at least three
families (Table 2). In three out of these 14 recurrent
mutations, we were able to indicate familial links between
probands, although we have not yet succeeded in connecting
all probands with these mutations. Pedigrees are provided of
these initially apparently unrelated families who could
subsequently be connected by genealogy after they appeared
to carry an identical disease-causing mutation (Fig. 1a–c).
Geographic characteristics are provided for probands that
have the most common recurrent mutations (Fig. 2a–c). The
subsequent paragraphs will discuss these mutations.
KCNQ1
The p.Tyr184Ser mutation in KCNQ1 (which means that,
on amino acid position 184 in the protein, the amino acid
tyrosine is replaced by the amino acid serine) is caused by
a missense mutation in the intracellular loop between the
second and third transmembrane segment of this potassium
ion channel. It has been found in eight LQT probands in
the Netherlands so far. The mutation is a frequently
reported mutation also outside the Netherlands (USA/
Japan) [22]. The mutation clearly co-segregates with the
disease, indicating that there is little doubt that the
mutation is pathogenic. Three of the eight Dutch probands
carrying this mutation were found to be genealogically
connected to each other. This family has a shared male
ancestor, born in 1721 (i.e., six generations from the
probands (Fig. 1a). Although the number of patients is
small and this mutation was found outside the Netherlands
as well, the postal codes of the known probands are closely
clustered in the region surrounding Utrecht, which
strengthens the idea of a founder effect rather than a
recurrent mutation (Fig. 2a).
KCNH2
The p.Arg582Cys mutation in KCNH2 (on position 582 in
the protein the amino acid arginine was changed into
cysteine) is caused by a missense mutation between the
fifth transmembrane segment and the pore (S5-pore) region
of the KCNH2-ion channel. The mutation is reported to be
present in at least 25 patients in the USA and The
Netherlands. In our population, it was detected in five
probands; two of these probands were genealogically linked
over six to seven generations through a male born in 1747
and his wife born in 1748 (Fig. 1b). The geographic
disparity of the five probands is quite large, as presented in
Fig. 2b.
SCN5A
The p.Ile1768Val (isoleucine is changed by the amino acid
valine on position 1768) mutation in SCN5A is caused by a
Table 2 Overview of the possible LQT founder mutations
Mutation Frequency (number of probands) AMC Frequency (number of probands) AZM Number of carriers
KCNQ1 p.Phe296Ser n=4 n=0 20
p.Tyr184Ser
a n=7 n=1 32
p.Gly314Ser n=2 n=2 (1 de novo) 7
p.Arg259Cys n=2 1 de novo n=2 13
p.Gly189Glu n=3 n=2 43
c.477+5 G>A n=3 n=0 6
Q356X n=2 n=1 9
p.Arg190Gln n=2 n=1 12
KCNH2 p.Arg582Cys
a n=2 n=3 43
L87P n=2 n=1 14
p.Thr613Met n=2 n=2 7
c.578-582delCCGTG n=1 n=4 36
p.Gly785Val n=3 n=0 47
SCN5A p.Ile1768Val
a n=9 n=0 37
aPedigrees of the connected families are provided in Fig. 1a– c. AMC Amsterdam Medical Center, AZM University Hospital Maastricht
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spanning the segment in domain 4 of the sodium ion
channel protein. Patients carrying this mutation often
present with severe arrhythmias or (aborted) sudden cardiac
death. This mutation was found in nine unrelated probands,
two of whom are connected. The ancestral couple was born
in 1758 (male) and 1774 (female), seven generations ago
(Fig. 1c). Most probands are living in one region (again
close to Utrecht), also strengthening the idea of a founder
mutation although there is some geographic disparity
(Fig. 2c).
Finally, it could be demonstrated that a recurrent
mutation is not necessarily a founder mutation. Whereas
the p.Arg259Cys and the p.Gly314Ser mutation in
KCNQ1 were both identified in four probands, it occurred
de novo in at least one of them. Neither of the pairs of
parents of the proband carried the causal mutation and the
family history was negative for sudden cardiac death or
LQTS (Table 2). Hence, the recurrent identification of these
mutations might also be based on the de novo mutation of a
nucleotide sensitive to spontaneous changes. Indeed, both
mutations occur at CpG dinucleotides known to be
mutation hotspots [23].
Discussion
Most patients with LQTS have mutations in genes, which
encode for cardiac ion channels or their subunits.
Worldwide, most families carry a KCNQ1 mutation (type
1 LQTS) or a KCNH2 mutation (type 2 LQTS). Both
genes encode for potassium channels (IKs and IKr,
respectively) in which a reduced outward current leads to
prolonged repolarisation and, hence, a prolonged QT
interval. Additional to classical risk factors as QTc interval
length, sex, age, and history of prior syncope, the risk
stratification of LQT1 and LQT2 patients significantly
depends of the location of the mutation within the gene
(transmembrane or C terminus in KCNQ1 and the
transmembrane pore region vs. N terminus, transmem-
brane nonpore, or C terminus regions in KCNH2)[ 22, 24].
Furthermore, the biophysical function of a mutation in
KCNQ1 patients (haploinsufficiency or dominant-negative
effects) and the topology (α-helical domain vs. the β-sheet
domain or other uncategorised locations) of the mutation
in KCNH2 patients are independent risk stratifiers for
cardiac events [22, 24]. Finally, the type of mutation
(nonmissense vs. missense) in the C terminus region of
KCNH2 determines the risks of cardiac events significant-
ly [22, 24, 25]. Patients with LQT3 have a defect in the
sodium channel gene SCN5A (type 3 LQTS). Here,
persistent inward sodium current underlies the prolonged
action potential duration.
Fig. 1 a Pedigree LQT1: p.Tyr184Ser. b Pedigree LQT2: p.
Arg582Cys. c Pedigree LQT3: p. Ile1768Val
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have a disease-causing mutation in one of these three genes
(LQT1-3). In general, the yield of genetic testing strongly
depends on the case: in 60% to 70% of cases with a definite
diagnosis and/or a disease-related family history, a mutation
is identified [18, 19, 26–28]. When all referrals are counted,
including asymptomatic patients with slightly prolonged
QT interval durations, the yield significantly drops to about
35% [18, 19, 26–28]. If the molecular screening is limited
to familial cases (>1 clinically affected individual or a
family history of unexplained sudden death at age≤
40 years), the yield can be as high as 90% [29].
In the series on Dutch inherited cardiac diseases
caused by a founder mutation, we analysed and
described which mutations were found at least three
times in apparently unrelated Dutch LQT probands. In
the Netherlands, so far, we do not seem to have clear
LQTS founder mutations, with the exception of the p.
Tyr1795_Glu1796insAsp in the SCN5A gene [20, 21].
However, LQTS-causing founder mutations have been
discovered in other parts of the world, i.e., South Africa,
Sweden, Saudi Arabia, and Finland [10–16]. An example
is the p.Ala341Val mutation, identified in at least 22
LQT1 families in South Africa. The disease allele in all of
these families descends from a common ancestor who
migrated from the Netherlands to South Africa more than
300 years ago [11–13]. Interestingly, as far as we know,
this mutation is not a recurrent mutation in the Dutch
population. Although these patients carry the same
underlying gene defect, there are significant phenotypical
differences. In general, the associated phenotype seems
to be highly malignant and even more malignant than
other mutations in the same region of the KCNQ1 gene
[26]. A recent study by Winbo et al. presents the
dominant-negative p.Tyr111Cys mutation in KCNQ1 in
80 carriers from 15 families of which eight are connected
with a common ancestor born 11 generations previously
in the inland of northern Sweden. Contrary to the
p.Ala341Val mutation, this mutation appears to be very
benign, with no cases of sudden cardiac death in its
population and only a single reported case of aborted
cardiac arrest [14].
In Finland, four mutations are frequently detected: the
p.Gly589Asp and the c.1129-2A>G (originally annotated
as IVS7-2A>G) in KCNQ1 and the p.Leu552Ser and
p.Arg176Trp mutations in KCNH2, accounting for up to
70% of the known genetic causes for Finnish LQTS [10,
15]. These Finnish founder mutations cause a slightly
prolonged QTc interval, and the phenotype seems to be
 Fig. 2 a Disparity of the p.Tyr184Ser mutation in KCNQ1. b
Disparity of the p.Arg582Cys mutation in KCNH2. c Disparity of
the p.Ile1768Val mutation in SCN5A
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mutation. The intron mutation c.387-5>A in KCNQ1 and
the p.Gln1070X mutation in KCNH2, both found homozy-
gously in consanguineous, but apparently unrelated, Saudi
Arabian families, appeared to be founders as well, since
both families had identical haplotypes [16]. In these
families, there are several severely affected individuals
due to homozygous mutation carriership.
We have not yet performed haplotype analysis in the
families with recurrent LQT mutations. However, the
described links in the three pedigrees (Fig. 1a, c) make it
likely that these recurrent mutations are indeed true founder
mutations.
Recognising founder mutations is important for several
reasons. First, it could significantly improve the turnaround
time of DNA diagnostics if this could start with searching
for frequent founder mutations. The results of DNA
diagnostics would be available much faster, followed by
fast available cascade screening of the family. Secondly, the
genotype–phenotype correlation of the particular mutation
can be studied extensively, which will improve risk
stratification and optimal treatment strategies in these
families. Furthermore, a population carrying a founder
mutation is particularly of interest for research purposes,
i.e., for the identification of other genetic variants that may
influence the phenotype (known as genetic modifiers). The
first evidence for such a genetic modifier in a LQTS
founder population was recently described by Crotti et al.
[30]. This study in the South African founder population
(the Ala341Val mutation in KCNQ1, see above) revealed
that common NOS1AP variants are associated with the
clinical severity of congenital LQTS. The QT duration of
carriers of the founder mutations and the NOS1AP variant
is significantly prolonged compared with the QT duration
of those patients who carry the founder mutation alone
[30]. Concerning LQTS, the NOS1AP is the first impor-
tant study of a series of modifiers, based on data of
founder populations.
The recurrent mutations that are “possible” founder
mutations in the Netherlands are listed in Table 2. Care
should be taken not to jump too prematurely to this
conclusion as there is evidence that both mutations
p.Arg259Cys and p.Gly314Ser can occur de novo. Spon-
taneous mutagenesis at hotspots may result in recurrent
mutations in unrelated probands.
The LQTS1 and LQTS2 recurrent mutations p.Tyr184Ser
and p.Arg582Cys, respectively, have a phenotype that is not
particularly benign or particularly malignant. However, in
the SCN5A p.Ile1768Val families, premature sudden death is
prevalent, and carriers of this particular mutation should have
close follow-up and timely treatment, which unfortunately in
this subtype may have to be the implantation of a device
(PM or ICD?).
Conclusions
We have identified recurrent mutations in all different
LQTS subtypes. In three of these families, a genealogical
link was found between (far-related) independent probands.
This supports the concept that some recurrent mutations are
indeed founder mutations. Haplotype analysis in these and
other families with a recurrent mutation is pertinent to
perform further research on the founder aspects of these
mutations. Eventually, this may result in a better under-
standing of mutation–disease relations and in better
tailoring of potentially life-saving treatment.
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